The board of ISR Immune System Regulation Holding AB (ISR) has signed a Memorandum of Understanding, with Beijing Kawin Technology Share-Holding Co., Ltd. (KAWIN), in order to develop ISRs immunolide ISR50 for Hepatitis B (HBV). ISR50 is a TLR agonist for an immunostimulatory treatment of HBV, a compound with a mode of action based on 2011 Nobel prize. Together with KAWIN, ISR will initiate pre-clinical testing in animal models of HBV evaluating the immunostimulatory properties of ISR50.

KAWIN has received a Right of First Refusal (ROFR), which stipulates that KAWIN has the license for the Chinese (PRC) market since KAWIN is financing all the studies. The objective is to explore, negotiate and agree on the detailed and definite terms of the potential license agreement by the 31 of May 2021.